Although VA-ECMO is generally considered a relative contraindication in patients with end-stage malignancy, the tumor in this case harbored a deletion mutation in exon 19 of EGFR, which is known to respond rapidly to the molecularly targeted agent osimertinib. Here, EGFR is linked to neoplasm.